Mohammad H Alshaer

Mohammad H Alshaer, Pharm.D., Ph.D.

Research Assistant Professor

Department: Pharmacotherapy & Translational Research
Business Phone: (352) 273-6803
Business Email: mshaer@ufl.edu

About Mohammad H Alshaer

Dr. Alshaer is a Research Assistant Professor at the Infectious Disease Pharmacokinetics Laboratory, Department of Pharmacotherapy and Translational Research, UF College of Pharmacy. Dr. Alshaer received a Pharm.D. from Jordan University of Science and Technology and a Ph.D. from University of Florida. He worked as a clinical specialist for six years, then joined UF College of Pharmacy as a graduate student/assistant. His research focuses on the pharmacokinetics/pharmacodynamics of antimicrobial therapy in patients with serious infections with special interest in beta-lactams, population pharmacokinetics, precision dosing, and antimicrobial exposure-response relationship in patients.

Accomplishments

International Student Achievement Award
2019 · University of Florida
Teaching Assistant Recognition Award
2019 · University of Florida
Grinter Fellowship
2016 · University of Florida

Research Profile

Open Researcher and Contributor ID (ORCID)

0000-0003-1432-5175

Areas of Interest
  • Antimicrobial resistance (AMR or AR)
  • Beta-lactams
  • MCMC simulation
  • Pharmacodynamics
  • Pharmacokinetics
  • Pharmacokinetics/pharmacodynamics
  • Population pharmacokinetics
  • Precision Health

Publications

2021
Cefepime population pharmacokinetics and target attainment in critically ill patients on continuous renal replacement therapy
Antimicrobial Agents and Chemotherapy. [DOI] 10.1128/aac.00144-21.
2021
Comment on: The case for ‘conservative pharmacotherapy’
Journal of Antimicrobial Chemotherapy. [DOI] https://doi.org/10.1093/jac/dkab087.
2021
Pharmacogenetic predictors of nevirapine pharmacokinetics in Ghanaian children living with HIV with or without TB coinfection.
Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases. [DOI] 10.1016/j.meegid.2021.104856. [PMID] 33839311.
2021
Population Pharmacokinetics and Significant Under-Dosing of Anti-Tuberculosis Medications in People with HIV and Critical Illness.
Antibiotics (Basel, Switzerland). 10(6) [DOI] 10.3390/antibiotics10060739. [PMID] 34207312.
2021
Provider perspectives on beta-lactam therapeutic drug monitoring programs in the critically ill: a protocol for a multicenter mixed-methods study.
Implementation science communications. 2(1) [DOI] 10.1186/s43058-021-00134-9. [PMID] 33762025.
2021
Using precision dosing to minimize cefepime-induced neurotoxicity: The challenge of targets.
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. [DOI] 10.1016/j.jiac.2021.02.020. [PMID] 33663932.
2020
A Systematic Review and Meta-analysis of Isoniazid Pharmacokinetics in Healthy Volunteers and Patients with Tuberculosis.
Clinical therapeutics. 42(11):e220-e241 [DOI] 10.1016/j.clinthera.2020.09.009. [PMID] 33032843.
2020
Chapter: Antituberculosis in pediatric patients
Book: Yaffe & Aranda Neonatal and Pediatric Pharmacology, 5th edition..
2020
Chapter: Drug assay methodologies, a primer for clinicians
Book 1: Infectious Diseases Self-Assessment Program, American College of Clinical Pharmacy.
2020
Comment on “Meropenem, Cefepime, and Piperacillin Protein Binding in Patient Samples”.
Therapeutic drug monitoring. 42(6) [DOI] 10.1097/FTD.0000000000000810. [PMID] 33197165.
2020
Determination of Rifampin Concentrations by Urine Colorimetry and Mobile Phone Readout for Personalized Dosing in Tuberculosis Treatment.
Journal of the Pediatric Infectious Diseases Society. [DOI] 10.1093/jpids/piaa024. [PMID] 32170944.
2020
Early therapeutic monitoring of β-lactams and associated therapy outcomes in critically ill patients
Journal of Antimicrobial Chemotherapy. 75(12):3644-3651 [DOI] 10.1093/jac/dkaa359.
2020
Ethionamide Population Pharmacokinetic Model and Target Attainment in Multidrug-Resistant Tuberculosis
Antimicrobial Agents and Chemotherapy. 64(9) [DOI] 10.1128/aac.00713-20.
2020
Evaluation of super-boosted lopinavir/ritonavir in combination with rifampicin in HIV-1-infected patients with tuberculosis
International Journal of Antimicrobial Agents. 55(2) [DOI] 10.1016/j.ijantimicag.2019.10.021.
2020
Meropenem, Cefepime, and Piperacillin Protein Binding in Patient Samples.
Therapeutic drug monitoring. 42(1):129-132 [DOI] 10.1097/FTD.0000000000000675. [PMID] 31318843.
2020
Pharmacokinetics of bedaquiline, delamanid and clofazimine in patients with multidrug-resistant tuberculosis
Journal of Antimicrobial Chemotherapy. [DOI] 10.1093/jac/dkaa550.
2020
Population Pharmacokinetics and Target Attainment of Cefepime in Critically Ill Patients and Guidance for Initial Dosing
Antimicrobial Agents and Chemotherapy. 64(9) [DOI] 10.1128/aac.00745-20.
2020
Population Pharmacokinetics of Linezolid in Tuberculosis Patients: Dosing Regimen Simulation and Target Attainment Analysis
Antimicrobial Agents and Chemotherapy. 64(10) [DOI] 10.1128/aac.01174-20.
2020
Variable linezolid exposure and response and the role of therapeutic drug monitoring: Case series
Clinical Case Reports. 8(7):1126-1129 [DOI] 10.1002/ccr3.2835. [PMID] 32695341.
2019
A Pharmacology Perspective on Simultaneous Tuberculosis and Hepatitis C Treatment
Antimicrobial Agents and Chemotherapy. 63(12) [DOI] 10.1128/aac.01215-19.
2019
Cycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis
Antimicrobial Agents and Chemotherapy. 63(5) [DOI] 10.1128/aac.00055-19.
2019
Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection
Antimicrobial Agents and Chemotherapy. 63(7) [DOI] 10.1128/aac.00279-19.
2018
Fixed-dose combination associated with faster time to smear conversion compared to separate tablets of anti-tuberculosis drugs in patients with poorly controlled diabetes and pulmonary tuberculosis in Qatar
BMC Infectious Diseases. 18(1) [DOI] 10.1186/s12879-018-3309-0. [PMID] 30089476.
2018
Perspectives for personalized therapy for patients with multidrug-resistant tuberculosis
Journal of Internal Medicine. 284(2):163-188 [DOI] 10.1111/joim.12780.
2018
Pharmacokinetics of tuberculosis drugs in HIV-infected patients from Irkutsk, Russian Federation: redefining drug activity
European Respiratory Journal. 51(5) [DOI] 10.1183/13993003.00109-2018. [PMID] 29599189.
2018
Protein Binding of First-Line Antituberculosis Drugs
Antimicrobial Agents and Chemotherapy. 62(7) [DOI] 10.1128/aac.00641-18.
2017
Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?
Expert Review of Clinical Pharmacology. 10(10):1027-1036 [DOI] 10.1080/17512433.2017.1366311.
2017
Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar.
BMC infectious diseases. 17(1) [DOI] 10.1186/s12879-017-2231-1. [PMID] 28152986.
2015
Evaluating the effectiveness and safety of hydrocortisone therapy in cancer patients with septic shock.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 21(4):274-9 [DOI] 10.1177/1078155214533738. [PMID] 24781452.
2015
Metoclopramide-induced asystolic cardiac arrest.
The Annals of pharmacotherapy. 49(5):610-1 [DOI] 10.1177/1060028015577446. [PMID] 25870445.
2014
Rifampicin as adjunct to colistin therapy in the treatment of multidrug-resistant Acinetobacter baumannii.
The Annals of pharmacotherapy. 48(6):766-71 [DOI] 10.1177/1060028014528306. [PMID] 24651164.
2013
Drug utilization pattern and cost for the treatment of severe sepsis and septic shock in critically ill cancer patients.
International journal of clinical pharmacy. 35(6):1245-50 [DOI] 10.1007/s11096-013-9860-2. [PMID] 24104762.
Use of Therapeutic Drug Monitoring to Characterize Cefepime-Induced Neurotoxicity
. [DOI] 10.1101/2020.08.13.250456.

Grants

May 2021 ACTIVE
Prevalence of Cefazolin Inoculum Effect in Mcthicillin Susceptible Staphylococcus aureus Bacteremia
Role: Co-Investigator
Funding: UF HEALTH SHANDS HOSPITAL

Teaching Profile

Courses Taught
2020-2021
PHA5782C Patient Care 2: Introduction to Infectious Disease and Oncology

Contact Details

Phones:
Business:
(352) 273-6803
Emails:
Business:
mshaer@ufl.edu